{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/allergic-rhinitis/prescribing-information/intranasal-anticholinergics/","result":{"pageContext":{"chapter":{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics","depth":2,"htmlHeader":"<!-- begin field 78fa85d6-6d09-4f55-9122-12b6d33aa474 --><h2>Intranasal anticholinergics</h2><!-- end field 78fa85d6-6d09-4f55-9122-12b6d33aa474 -->","summary":"","htmlStringContent":"<!-- begin item 4dbccef8-7b6a-44b9-b37c-c3b6ab2a50db --><!-- end item 4dbccef8-7b6a-44b9-b37c-c3b6ab2a50db -->","topic":{"id":"e84371ef-9d30-56df-8358-1520fb2c324f","topicId":"0473d89c-2999-40d1-911f-d265b4bd3942","topicName":"Allergic rhinitis","slug":"allergic-rhinitis","lastRevised":"Last revised in September 2018","chapters":[{"id":"5fa28a05-233b-5de6-aee8-ea0327f3c7d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ea1f0c07-a5f8-599b-9b96-71ef8590b2a6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes"},{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update"}]},{"id":"392391e3-b09a-5cab-ae2a-040eb039abd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"292568d8-a1f5-5b8f-a13d-f3c014fa8e95","slug":"goals","fullItemName":"Goals"},{"id":"2f7129b7-e08b-5e5f-997c-4b661ce0a778","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8062582a-18e3-58d5-a8cb-f9689e259444","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1e562233-ae40-5755-abc7-71551f4cea02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ccab909c-169d-52aa-ac0a-9d425f89a99c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37d61d5d-e2f1-58ef-9c6a-27c4011784f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84432cb8-00ce-599e-9e05-3493755dacd6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f59296af-8e0a-509d-b8f3-692efd2bdb92","slug":"definition","fullItemName":"Definition"},{"id":"37020833-afb2-529a-975a-1f1a7a5db2ef","slug":"causes","fullItemName":"Causes"},{"id":"962f75f0-d73d-5c7c-aaf4-d08fc672e6be","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ab993d04-4c7b-59cd-9e56-2e0ef7fdc9db","slug":"complications","fullItemName":"Complications"},{"id":"68b348fd-2864-5da4-8687-6d8c25004f1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"80c9e7d3-3315-55b9-98fb-2261b95a1b5c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3cc3ef09-2238-5504-8781-48914ad6a4c9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5a3f0e38-3f88-5049-beaa-f4cb26499dc6","slug":"assessment","fullItemName":"Assessment"},{"id":"5bd413c7-0398-5b71-acad-a5699c7c703b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","fullItemName":"Management","slug":"management","subChapters":[{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"760f3c4d-0984-5865-acbe-65d470f66518","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a47a2aa5-0821-5bf5-987b-2397ac2c982f","slug":"intranasal-antihistamines","fullItemName":"Intranasal antihistamines"},{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"5507fb81-aa18-5a21-b619-8db3c3c78e80","slug":"intranasal-cromones","fullItemName":"Intranasal cromones"},{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants"},{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics"},{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists"}]},{"id":"f3877d58-da5a-5655-8752-49e87f3a410b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87371e7f-8741-54ef-9af6-339f8f0b9285","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"318f5be9-46cf-5fb9-b28c-7ebb4a901904","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49c3da95-9d4f-5a93-a7ca-e71965fcb981","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"33a2085c-95d6-5004-8f1f-50a08684c638","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b1a0d4a-fd5e-5b81-9293-5b2f004871cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"735b627c-7d7e-58b8-8196-b4972220342b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"92889a85-b6e7-58f3-9f09-eae6ca76386c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"760f3c4d-0984-5865-acbe-65d470f66518","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"17078b8f-e45e-5d79-b48f-93b79309818e","slug":"dose-regimens","fullItemName":"Dose regimens","depth":3,"htmlHeader":"<!-- begin field e7809ec5-aeba-4e1b-804b-a96c00bcc468 --><h3>Dose regimens</h3><!-- end field e7809ec5-aeba-4e1b-804b-a96c00bcc468 -->","summary":"","htmlStringContent":"<!-- begin item 72c251b9-3559-426d-bf6e-a96c00bcc3a2 --><!-- begin field bef86597-68c1-4150-aa46-a96c00bcc468 --><ul><li><strong>Intranasal ipratropium bromide is licensed for the management of rhinorrhoea associated with allergic rhinitis:</strong><ul><li>For children aged 12–17 years — two sprays 2–3 times a day, dose to be sprayed into each nostril.</li><li>For adults — two sprays 2–3 times a day, dose to be sprayed into each nostril.</li><li>Care should be taken to avoid spraying near the eyes, to reduce the risk of ocular complications.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field bef86597-68c1-4150-aa46-a96c00bcc468 --><!-- end item 72c251b9-3559-426d-bf6e-a96c00bcc3a2 -->","subChapters":[]},{"id":"16312249-4b56-5813-9bae-16ab1521f0cf","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 6614ac47-ba94-4f7f-aa4b-a96800dcdc25 --><h3>Contraindications and cautions</h3><!-- end field 6614ac47-ba94-4f7f-aa4b-a96800dcdc25 -->","summary":"","htmlStringContent":"<!-- begin item 9d6897f2-633d-4d63-b594-a96800dcdbe6 --><!-- begin field 52d9f04b-ef7d-495e-b548-a96800dcdc25 --><ul><li><strong>Prescribe intranasal ipratropium bromide with caution to people with:</strong><ul><li>Cystic fibrosis.</li><li>Bladder outflow obstruction and benign prostatic hyperplasia or enlargement (in men).</li><li>At risk of angle-closure glaucoma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 52d9f04b-ef7d-495e-b548-a96800dcdc25 --><!-- end item 9d6897f2-633d-4d63-b594-a96800dcdbe6 -->","subChapters":[]},{"id":"39c7d785-70b7-5a4e-9762-16c761a80966","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b56d6e7a-2f55-464e-9dae-a96800dce914 --><h3>Adverse effects</h3><!-- end field b56d6e7a-2f55-464e-9dae-a96800dce914 -->","summary":"","htmlStringContent":"<!-- begin item e71e10b1-fddd-40e9-86ab-a96800dce8ce --><!-- begin field 650a764d-1c2a-401f-b8b1-a96800dce914 --><ul><li><strong>Possible adverse effects with intranasal ipratropium bromide include:</strong><ul><li>Epistaxis, nasal dryness and irritation, headache, and nausea.</li><li>Rarely, gastro-intestinal motility disturbances, palpitations, and urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field 650a764d-1c2a-401f-b8b1-a96800dce914 --><!-- end item e71e10b1-fddd-40e9-86ab-a96800dce8ce -->","subChapters":[]},{"id":"10afe638-283f-5e40-886c-3547e5ca95f5","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e3fa5616-3d19-4c36-968e-a96800dcf3b0 --><h3>Drug interactions</h3><!-- end field e3fa5616-3d19-4c36-968e-a96800dcf3b0 -->","summary":"","htmlStringContent":"<!-- begin item 3418d152-99b1-44de-a97f-a96800dcf369 --><!-- begin field 5a509fa8-da5b-4a0b-94eb-a96800dcf3b0 --><ul><li><strong>Possible drug interactions with intranasal ipratropium bromide include:</strong><ul><li>Antimuscarinic effects when combined with drugs such as:<ul><li>Amantadine, amitriptyline, baclofen, chlorphenamine, chlorpromazine, clomipramine, cyclizine, dosulepin, doxepin, glycopyrronium, haloperidol, hydroxyzine, hyoscine, imipramine, levomepromazine, lofepramine, nefopam, nortriptyline, oxybutynin, pimozide, prochlorperazine, procyclidine, solifenacin, tiotropium, tolterodine, and umeclidinium.</li></ul></li><li>In addition:<ul><li>Formoterol is predicted to increase the risk of glaucoma when given with ipratropium.</li><li>Ipratropium decreases the absorption of levodopa.</li><li>Salbutamol is predicted to increase the risk of glaucoma when given with ipratropium.</li><li>Salmeterol is predicted to increase the risk of glaucoma when given with ipratropium.</li><li>Terbutaline is predicted to increase the risk of glaucoma when given with ipratropium.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 5a509fa8-da5b-4a0b-94eb-a96800dcf3b0 --><!-- end item 3418d152-99b1-44de-a97f-a96800dcf369 -->","subChapters":[]},{"id":"1c1abd11-8143-5360-9832-12a4f7f0abfa","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 8ea01c93-00d1-4bac-bf71-a96c00c35387 --><h3>Pregnancy and breastfeeding</h3><!-- end field 8ea01c93-00d1-4bac-bf71-a96c00c35387 -->","summary":"","htmlStringContent":"<!-- begin item 81433bf3-604c-4147-8316-a96c00c3533d --><!-- begin field 749b1b2b-00d1-47e0-bd1e-a96c00c35387 --><h4>Pregnancy</h4><ul><li>The manufacturer advises use only if the potential benefit outweighs the risk.</li></ul><h4>Breastfeeding</h4><ul><li>There is no specific information available — the manufacturer advises only use if the potential benefit outweighs risk.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 749b1b2b-00d1-47e0-bd1e-a96c00c35387 --><!-- end item 81433bf3-604c-4147-8316-a96c00c3533d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}